Abstract

Ocrelizumab is a high-efficacy disease modifying therapy (DMT) for patients with relapsing remitting multiple sclerosis (RRMS). To assess the socioeconomic value of ocrelizumab in RRMS compared with teriflunomide, dimethyl fumarate, and cladribine in Canada.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call